Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

Company Overview - Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients [3] - The company specializes in antibody-engineering and innovative target identification to create next-generation antibody therapeutics [3] Product Pipeline - Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, including: - IPH4502, a Nectin-4 ADC developed for solid tumors - Lacutamab, an anti-KIR3DL2 antibody for cutaneous T cell lymphomas and peripheral T cell lymphomas - Monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca for non-small cell lung cancer [4] Collaborations - The company has established partnerships with leading biopharmaceutical companies such as Sanofi and AstraZeneca, as well as renowned academic and research institutions to enhance innovation in immuno-oncology [5] Share Information - As of February 19, 2026, Innate Pharma has a total of 93,743,243 ordinary shares and 6,140 Preferred Shares from 2016 and 7,581 from 2017, resulting in a total of 94,484,443 theoretical voting rights [1] - The total number of exercisable voting rights is 94,465,868, calculated without considering shares held in treasury or with suspended voting rights [2]